Study of Healthy Cohort for Early Detection of Cancer


Cancer produces a significant burden on society with a majority diagnosed at late stages when the chance of cure is low. Early diagnosis improves patient outcomes. Data consisting of lifestyle factors, medications, physical activity, years before conventional cancer diagnosis is also worthwhile for to determine early detection. This is only achievable with longitudinal tracking of a large number of healthy individuals and identifying those who do develop cancer over time.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2027

Detailed Description

To conduct a longitudinal cohort study of patients who do not have a malignancy at the time of enrollment and are followed over a 20 year period to see if patients develop a malignancy and associate clinical and lifestyle factors as well as collection of blood. All adults 18 years of age and older undergoing upper or lower endoscopy for routine medical care will be eligible for this study.

Clinical Trial Outcome Measures

Primary Measures

  • Development of malignancy
    • Time Frame: Up to 20 years
    • Assessment of participants for the development of malignancy during a 20-year follow-up period.

Secondary Measures

  • Development of biomarkers
    • Time Frame: Up to 20 years
    • To identify proteins, RNA and DNA that have changes in expression in those who develop cancer.

Participating in This Clinical Trial

Inclusion Criteria

  • All adults 18 years of age of older undergoing upper or lower endoscopy for routine medical care. Exclusion Criteria:

  • Persons with current malignancy – Persons with history of malignancy and treatment within last 5 years of enrollment, excluding non-melanoma skin cancer or cervical in-situ. – Persons who are unable or unwilling to provide repeat blood samples and complete follow-up questionnaires – Persons who lack the capacity to provide consent – Persons who do not speak English – Persons who are visually or hearing impaired.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Johns Hopkins University
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Elham Afghani, Principal Investigator, Johns Hopkins University
  • Overall Contact(s)
    • Elham Afghani, 410-614-6708,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.